Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases
However, oral bioavailability is only about 1%, meaning you need a much higher absolute dose to achieve comparable blood levels to the injectable form
Can J Diabetes 2020;44:575-91
adults report having taken a GLP-1 agonist medication
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for the Management of Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review
Conservative care trials have included guided weight loss, dietitian input, compression garments, occasional antibiotic courses for infection and a documented six-month trial of mobilizing physiotherapy to no lasting effect